Corallo Carmelo, Al-Adhami Abdullah S, Jamieson Nigel, Valle Juan, Radhakrishna Ganesh, Moir John, Albazaz Raneem
Department of Radiology, St James's University Hospital, Leeds LS9 7TF, United Kingdom.
Department of Radiology, Glasgow Royal Infirmary, Glasgow G31 2ER, United Kingdom.
Br J Radiol. 2025 Jan 1;98(1165):13-26. doi: 10.1093/bjr/tqae217.
Pancreatic ductal adenocarcinoma continues to have a poor prognosis, although recent advances in neoadjuvant treatments (NATs) have provided some hope. Imaging assessment of suspected tumours can be challenging and requires a specific approach, with pancreas protocol CT being the primary imaging modality for staging with other modalities used as problem-solving tools to facilitate appropriate management. Imaging assessment post NAT can be particularly difficult due to a current lack of robust radiological criteria to predict response and differentiate treatment induced fibrosis/inflammation from residual tumour. This review aims to provide an update of pancreatic ductal adenocarcinoma with particular focus on three points: tumour staging pre- and post-NAT including vascular assessment, structured reporting with introduction of the PAncreatic Cancer reporting Template-UK (PACT-UK) radiology template, and the potential future role of artificial intelligence in the diagnosis and staging of pancreatic cancer.
尽管新辅助治疗(NATs)方面的最新进展带来了一些希望,但胰腺导管腺癌的预后仍然很差。对疑似肿瘤进行影像学评估具有挑战性,需要采用特定方法,胰腺协议CT是分期的主要影像学方式,其他方式则用作解决问题的工具以促进合理管理。由于目前缺乏可靠的放射学标准来预测反应并区分治疗引起的纤维化/炎症与残留肿瘤,NAT后的影像学评估可能特别困难。本综述旨在提供胰腺导管腺癌的最新情况,特别关注三点:NAT前后的肿瘤分期,包括血管评估;引入英国胰腺癌报告模板(PACT-UK)放射学模板进行结构化报告;以及人工智能在胰腺癌诊断和分期中的潜在未来作用。